BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mauss S, Hueppe D, John C, Goelz J, Heyne R, Moeller B, Link R, Teuber G, Herrmann A, Spelter M. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat. 2011;18:e81-e90. [PMID: 20849436 DOI: 10.1111/j.1365-2893.2010.01372.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Iwasaki Y, Araki Y, Taniguchi H, Okamoto R, Kobashi H, Ikeda F, Miyake Y, Takaki A, Yamamoto K. Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1. J Med Virol 2015;87:625-33. [PMID: 25611729 DOI: 10.1002/jmv.24097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Bota S, Sporea I, Şirli R, Neghină AM, Popescu A, Străin M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin Drug Investig 2013;33:325-31. [PMID: 23532802 DOI: 10.1007/s40261-013-0074-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
3 Birerdinc A, Afendy A, Stepanova M, Younossi I, Baranova A, Younossi ZM. Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). Brain Behav 2012;2:525-31. [PMID: 23139898 DOI: 10.1002/brb3.72] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zayed N, Awad AB, El-Akel W, Doss W, Awad T, Radwan A, Mabrouk M. The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2013;37:254-61. [PMID: 23141214 DOI: 10.1016/j.clinre.2012.09.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
5 El-karaksy HM, Sharaf SA, Mandour IA, Mogahed EA, Rady NH, El- Mougy FA. Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection. Human Immunology 2016;77:1248-53. [DOI: 10.1016/j.humimm.2016.09.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Gidding HF, Law MG, Amin J, Ostapowicz G, Weltman M, Macdonald GA, Sasadeusz JJ, Haber PA, George J, Dore GJ. Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia 2012;196:633-7. [DOI: 10.5694/mja12.10014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
7 Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis. 2013;56:806-816. [PMID: 23223596 DOI: 10.1093/cid/cis1007] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 10.6] [Reference Citation Analysis]
8 Queiroga Mde L, Paraná R, Medeiros Filho JE, Figueiredo GC, Araújo AP, Leite HW, Aquino Ide S, Melo Neto LH. GAMMA GLUTAMYLTRANSFERASE IMPACT IN THERAPEUTIC RESPONSE OF CHRONIC HEPATITIS C: a systematic review of the literature. Arq Gastroenterol 2015;52:239-46. [PMID: 26486294 DOI: 10.1590/S0004-28032015000300016] [Reference Citation Analysis]
9 Barcaui HS, Tavares GC, May SB, Brandão-Mello CE, Amendola Pires MM, Barroso PF. Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil. PLoS One 2013;8:e67734. [PMID: 23874441 DOI: 10.1371/journal.pone.0067734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
10 Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon 2012;12:e6151. [PMID: 23087759 DOI: 10.5812/hepatmon.6151] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
11 Pavón-Castillero EJ, Muñoz-de-Rueda P, López-Segura R, Gila A, Quiles R, Muñoz-Gámez JA, Carazo A, Martínez P, Ruiz-Extremera A, Salmerón J. Importance of IL-10 and IL-6 during chronic hepatitis C genotype-1 treatment and their relation with IL28B. Cytokine 2013;61:595-601. [PMID: 23159283 DOI: 10.1016/j.cyto.2012.10.009] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
12 Mandorfer M, Reiberger T, Payer BA, Breitenecker F, Aichelburg MC, Obermayer-pietsch B, Rieger A, Puoti M, Zangerle R, Trauner M, Peck-radosavljevic M. Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels. J Viral Hepat 2014;21:33-41. [DOI: 10.1111/jvh.12118] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
13 Park SH, Park CK, Lee JW, Kim YS, Jeong SH, Kim YS, Kim JH, Hwang SG, Rim KS, Yim HJ, Cheong JY, Cho SW, Lee JS, Park YM, Jang JW, Lee CK, Shon JH, Yang JM, Ju YS. Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut Liver 2012;6:98-106. [PMID: 22375178 DOI: 10.5009/gnl.2012.6.1.98] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ladero JM, Martin EG, Fernández C, Carballo M, Devesa MJ, Martínez C, Suárez A, Díaz-Rubio M, Agúndez JA. Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data. J Gastroenterol Hepatol. 2012;27:279-285. [PMID: 21722179 DOI: 10.1111/j.1440-1746.2011.06834.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
15 Speičienė D, Kotovienė L, Mickevičius A, Liakina V, Valantinas J. EFFICACY OF TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION “UNDER REAL LIFE“ CONDITIONS. Medicinos teorija ir praktika 2014;21:23-32. [DOI: 10.15591/mtp.2015.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol 2013; 19(47): 8963-8973 [PMID: 24379621 DOI: 10.3748/wjg.v19.i47.8963] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
17 Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Carman B, Delahooke TE, Dillon JF, Goldberg DJ, Kennedy N. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. Eur J Gastroenterol Hepatol. 2012;24:646-655. [PMID: 22433796 DOI: 10.1097/meg.0b013e32835201a4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]